Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹632.10
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹116.32B
Enterprise Value₹118.10B
Total Cash (Recent Filing)₹535.50M
Total Debt (Recent Filing)₹5.93B
Price to Earnings (P/E)50.0
Beta0.75
Next Earnings
Aug 06, 2026Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)7.01
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.63
Price to Sales (P/S)4.43
P/FCF Ratio-90.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.55
Revenue Forecast (FY)₹18.29B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin RecoveryThe company delivered accelerating revenue growth and a sharp profitability recovery in FY2026, with double-digit net and strong operating margins. Sustained top-line momentum and improved operating margins create a stronger earnings base over the next 2–6 months, supporting reinvestment and credit metrics if maintained.
Conservative Leverage And Balance Sheet CapacityLower leverage versus prior years implies a conservatively structured balance sheet with room to fund growth or absorb shocks. This durable financial flexibility reduces default risk, supports capital allocation for R&D or capacity, and gives management optionality to pursue strategic investments over the medium term.
Specialty APIs And Contract Manufacturing ModelA business mix centered on complex/specialty APIs and contract manufacturing yields higher technical barriers, longer customer relationships, and diversification across owned products and CMO work. Structurally, this supports pricing power, repeatable revenue streams and resilience against commodity competition over months to years.
Bears Say
Persistent Negative Free Cash FlowConsistent negative free cash flow means reported profits are not generating surplus cash after investments. Over the medium term this constrains the firm's ability to self-fund capex, reduce debt, return capital to shareholders, or absorb shocks, increasing reliance on external financing and execution risk.
Historically Weak Returns On EquityA history of low or negative ROE indicates the company has struggled to convert its equity base into sustained shareholder returns. Even with a 2026 rebound, inconsistent returns raise questions about capital allocation effectiveness and suggest longer-term improvement is required to justify reinvestment.
Earnings And Margin VolatilityMaterial swings in gross and net margins point to exposure to input costs, product mix shifts, or pricing pressure. Margin instability reduces predictability of future cash flows and complicates budgeting and strategic decisions, weakening competitive positioning versus steadier-margin peers over the medium term.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹632.10 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹116.32B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is Aug 06, 2026 which is in 27 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on May 22, 2026. The company reported ₹5.5 earnings per share for the quarter, beating the consensus estimate of ₹3.3 by ₹2.2.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate is 4.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹5.5 in its last earnings report, beating expectations of ₹3.3. Following the earnings report the stock price went up 3.778%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Jubilant Pharmova Limited
―
Strides Pharma Science Ltd
―